Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No one ever said any of it. But I do remember guaranteed approval in July of 2016 lol lol
No one ever said any of it. But I do remember guaranteed approval in July of 2016 lol lol
I remember these "declarations" that have failed to become reality as well. Welcome back Couch.
I remember Elite would never have enough money for a phase 3 trial......
.........that BK was guaranteed in 2016 ------- err that was 2017 ------- must be 2018.
..........a RS by 2017 - DOUBLE WHOOPSY!!!
.........that the .02 cent shares were coming any day now for the past 3 years. lol lol lol
Thank you for the response Nasdaq.
Great question lets turn it over to the MB. I think it would, but this is only my opinion.
Hi NASDAQ2020. Question for you. Do you know if this would qualify for an expedited review by the FDA because of this being an ADF product?
GENERIC ADF OXYCONTIN
First and Only generic abuse deterrent Opiod in the USA
Watch for it !
$2.5 Billion dollar market
I do agree with you on this. Once the FDA objection letter is resolved and the Percocet/Norco ANDA's are approved, the share price should appreciate substantially.
You're right the lid is getting to blow off this thing any day now.
Because that is what every investor wants is maxed out AS and reverse splits. Brilliant strategy.
The number of outstanding shares is immaterial. There are R&D companies that have maxed out their A/S, completed a RS and continued on with their business plan which includes the selling of shares to finance their drug development programs. Of these entities, some of them report revenues but, by and large, their ultimate goal is to R&D products for delivery to market so that they eventually will become cash flow positive. Yes, Elite has a pipeline of approved products on the market and right now they have several products under ANDA review by the FDA and even more products currently being developed and still more drugs that have been targeted for development.
That is not a case in point. Beginning finance 101 teaches shares outstanding is a basic factor in stock price. 800M shares outstanding is a far cry from AVXL's 40M shares outstanding.
Please don't disregard the reality of Elite's situation.
Savvy investors also recognize there are pharmacies who are developmental in nature, have no revenue but do have the potential to become cash flow positive if they can launch one or more of their products. They also trade at much higher prices than ELTP. Yes, it would be nice for Elite to be cash flow positive but Elite is primarily a development company as well. This has been stated in previous CC's.
No, it is the savvy investors who realize the critical need to be cash flow positive. This game of charades only lasts so long. Great attempt at trying to justify the lack of basic business fundamentals though.
Elite Pharmaceuticals' (ELTP) CEO Nasrat Hakim on Q1 2018 Results - Earnings Call Transcript:
https://seekingalpha.com/article/4098297-elite-pharmaceuticals-eltp-ceo-nasrat-hakim-q1-2018-results-earnings-call-transcript?part=single
Thanks for the chuckle. That was somewhat morbid but funny none the less.
Yeah, big news tomorrow. I can sense my middle finger acting up.
Could be news of the 10-Q1 being filed this week. The last 10-Q1 was filed on August 9/2016 and the year before that was August 10/2015.
I'm sensing news tomorrow. My big toe is acting up.
Well one of my DD sources is information disseminated by the company and I place far more credibility on this source as opposed to unproven, unsubstantiated opinions.
That is s mistake, relying on the company for the truth about elite
All good points. I agree 100%.
I am only a shareholder. . .not an insider. I rely upon information disseminated by the company to know what is going on. Nobody knows on the outside of it's a big "zip" or not unless you are an insider which of course you are not.
Yes a romantic dinner meeting between naz and the Chinese guy. Then a big zip
And he should be proud. . .good for him.
Were you not disputing the fact that Nasrat had met with Puracap? All I did was provide proof of a meeting. . .in plain english. Geez
In plain english. . .Nasrat met with a Puracap CEO on February 14/2017.
"We are working with them, they seem to be very interested. I met with their CEO, this may sound like a joke, but it’s not. Literally him and I met on Valentine’s Day, we had dinner on Valentine’s Day the last time was in February, negotiating the new contract and during that time"
https://seekingalpha.com/article/4081851-elite-pharmaceuticals-eltp-ceo-nasrat-hakim-q4-2017-results-earnings-call-transcript?part=single
I completely disagree.
I dont believe anyone is rooting for Elites failure
now 2¢ is guaranteed in the near future of this mess.
There were never any .02 predictions
how about some truth re predictions
There were never any .02 predictions
There were never any .02 predictions, BUT there sure were a few other doozies
and now 2¢ is guaranteed in the near future of this mess.
I agree 100% that's why the longs will see sub penny before long.
My DD strongly disagrees with this opinion. And really that's all it it is. . .just an opinion.
The current fundamentals are worse now than they were three years ago
$2.00 is more likely to happen given the current fundamentals in place rather than the nonsensical, ludicrous prediction of 2 cents.
LOL and $2 dollars longer than that, tell me is the PPS closer to 2¢ or $2 dollars!!!
This BS prediction has been out there for the third year now. LMAO
LOL ELTP will see sub-penny.
Exactly. I have been here long enough to know Nasrat has never promised no efficacy trial would be required.
There will be no proof/link that Nasrat promised no Efficacy trial. He has always stated he didn't think they would be required but he also stated he might and if the FDA asked for one Elite would provide one. Pesky facts.
The below quote came from a PR dated March 5, 2014. This is the alleged promise from Nasrat?. . .ELI-200 is expected to be filed this year. This constitutes a promise? Really? There is nothing here that is definitive as in making a "promise" would imply.
oh, here is the promise from Nasrat:
"As I have stated before, we have set in motion several initiatives that will have significant impact on Elite’s future,” commented Nasrat Hakim, Elite’s President and CEO. “Following the success of the pilot bioequivalence study in December for ELI-201, we are delighted with the results of this pivotal bioequivalence clinical study for ELI-200, our second opioid abuse deterrent product. ELI-200 is expected to be filed this year and will be the first NDA product filed by Elite with the U.S. Food and Drug Administration.”
Well so far I have only seen unsubstantiated opinions. . . no links, no verifiable info, no FACTS for that matter.
actually I could not care less if you are convinced, my job here is to state the FACTS
Hmmmmmmm. . .no, not convinced at all. Thanks though.
Lol yeah he said he needed it after he said he did not lol. By the way I said all throughout 2014 that it would be needed
The PR you reference is dated September 9/2014 and the more recent info I posted in the link is dated November 19/2014. Nasrat has repeatedly stated ELTP was in constant contact with the FDA in regard to ELI200 (SequestOx). Do you think in that period of time the FDA advised Nasrat of the possible efficacy trial that may be required? Hence the reference to the trial during the CC on November 19.
all you have to do is look at 2014 when he promised NDA submission by the end of the year
Provide a verifiable source where Nasrat actually said no efficacy trial would be required. I'll be waiting.
hmmmmmm I was told that elite did not need an efficacy study.
right, nasrat said that AFTER he realized that the FDA was not going to buy the crazy notion that no efficacy trial was needed. thanks
More BS as usual.
hmmmmmm I was told that elite did not need an efficacy study.
Thank you and GLTU as well.
I am not trying to convince you, good luck
Thank you for convincing me. LMAO
we know there is a credibility gap
Has SequestOx been stopped as in. . .permanently shut down? NO. Delay. . .yes. The NDA process is continuing. Last I heard, ELTP is conducting BE trials in preparation for resubmission later this year. TMAX results are scheduled to be released next month.
How about the CEO stating "the FDA cant stop us"??
I am still not convinced. Show me some specific, credibile examples of this "credibility gap" you speak of.
many many sources, seen daily
Please enlighten me as to who is saying there is a "credibility gap". Where is the source?
not so ludicrous if one considers the credibility gap faced by eltp
Complete nonsense. No pharma has ever posted the minutes of a FDA meeting and now it's expected that ELTP do this. What a ludicrous request.
perhaps, given the lack of trust in management that would be warranted in this case.
Show me an example where another pharma has ever posted verbatim minutes of an FDA meeting. I'll be waiting.
Question for ELITE: Where are the minutes from the FDA meeting?
I would disagree. If this was a complete restart on a new formulation then a new BE trial would be required and the expected results in July would not happen. No. . .in my opinion Elite/Camargo have recruited/are recruiting replacement candidates for the ones who were exluded and are continuing with the current BE trial.
My guess is that the path (out of three) that they chose didn't work. And now they are trying another one. just a guess
The complaint was filed two years ago (May 17,2015). Obviously, the SEC has concluded the complaint is a non-issue otherwise we would have heard something (punitive action) by now.
Information of an alleged SEC complaint against the CEO is important information for shareholders.